Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of GLA5PR in Subjects with Varying Renal Function
NCT03963362Phase 1Unknown
- Sponsor
- GL Pharm Tech Corp
- Start
- Sep 2019
- Primary completion
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of pregabalin in neuropathic pain (5 arms), sponsored by GL Pharm Tech Corp. Primary endpoints: Maximum Plasma Concentration of Pregabalin at 72 hours and Area Under the Curve to Last Quantifiable Concentration of Pregabalin at 72 hours. Status: unknown.
02
Drugs
pregabalin
03
Conditions
neuropathic pain
Beyond the preview
Go deeper on NCT03963362.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03963362.